Publications:

1. Di Malta C, Siciliano D, Calcagni A, Monfregola J, Punzi S, Pastore N, Eastes AN, Davis O, De Cegli R, Zampelli A, Giovannantonio LG, Nusco E, Platt N, Guida A, Ogmundsdottir MH, Lanfrancone L, Perera RM, Zoncu R, Pelicci PG, Settembre C, Ballabio A. Transcriptional activation of RagD GTPase controls mTORC1 and promotes cancer growth. Science, 2017 June 16; 356:1188-1192. (pubmed

2. Castellano BM, Thelan AM, Moldavski O, Feltes M, van der Welle RE, Mydock-McGrane L, Jiang X, van Eijkeren RJ, Davis OB, Louie SM, Perera RM, Covey DF, Nomura DK, Ory DS, Zoncu R. Lysosomal cholesterol activates mTORC1 via an SLC38A9-Niemann-Pick C1 signaling complex. Science, 2017 Mar 24; 355:1306-1311. (pubmed

3. Perera RM*, Zoncu R*. The lysosome as a regulatory hub. Ann Rev Cell Dev Biol, 2016 Oct 6; 32:223-253. (pubmed) [*co-corresponding] 

4. Atshuler-Keylin S, Shinoda K, Hasegawa Y, Ikeda K, Hong H, Kang Q, Yang Y, Perera RM, Debnath J, Kajimura K. Beige adipocyte maintenance is regulated by autophagy-induced mitochondrial clearance. Cell Metabolism, 2016 Sep 13;24(3):402-19. (pubmed)

5. Perera RM*, Bardeesy, N*. Pancreatic cancer metabolism: Breaking it down to build it back up. Cancer Discov, 2015 Nov 3 (pubmed). [*co-corresponding]

6. Perera RM, Stoykova S, Nicolay BN, Ross K, Fitamant J, Boukhali M, Lengrand J, Deshpande V, Selig MK, Ferrone CR, Settleman J, Stephanopoulos G, Dyson NJ, Zoncu R, Ramaswamy S, Haas W, Bardeesy N. Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism. Nature, 2015 Aug 20; 524(7565):361-5.(pubmed)

           - Highlighted in "Research Watch": MiT/TFE Proteins Mediate Metabolic Reprogramming in Pancreatic              Cancer.   Cancer Discov 2015 Jul 23 (pubmed)

          - Highlighted : Autophagy: Surviving Stress in Pancreatic Cancer.                                                                                          Nature Rev Cancer 2015 Aug 24 (pubmed)                                                                           

7. Fitamant J, Kottakis F, Benhamouche S, Tian H, Chuvin N, Parachoniak CA, Nagle JM, Perera RM, Lapouge M, Deshpande V, Zhu AX, Lai A, Min B, Hoshida Y, Avruch J, Sia D, Camprecios G, McClatchey AI, Llovet JM, Morrissey D, Raj L, Bardeesy N. YAP inhibition restores hepatocyte differentiation in advanced HCC, leading to tumor regression. Cell Reports, 2015 Mar 17; 10(10):1692-1707. (pubmed)

8. Lee JJ*, Perera RM*, Wang, H, Wu, D, Lie XS, Han S, Fitamant J, Jones, PD, Ghanta KL, Kawano S, Nagle JM, Deshpande V, Boucher Y, Kato T, Chen JK, Willmann JK, Bardeesy N, Beachy PA. Stromal response to Hedgehog signaling restrains pancreatic cancer progression. PNAS, 2014 Jul 29; 111(30):E3091-100.    *equal contributors co-corresponding (pubmed)

- Editors choice highlight: Complex roles for Hedgehog signaling in pancreatic cancer. Sci Signal, 2014 Aug 5; 7(337):204

9. Heilmann AM, Perera RM, Ecker V, Nicolay BN, Bardeesy N, Benes CH, and Dyson NJ. CDK4/6 and IGF1R/IR inhibitors synergize to suppress growth of p16INK4A-deficient pancreatic cancers. Cancer Research, 2014 Jul 15; 74(14):3947-58. (pubmed)

10. Son J, Lyssiotis CA, Ying H, Wang X, Huan S, Ligorio M, Perera RM, Ferrone CR, Mullarky E, Shyh-Chang N, Kang Y, Fleming JB, Bardeesy N, Asara, JM, Haigis MC, DePinho RA, Cantley LC, Kimmelman AC. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature, 2013 Apr 4; 496(7443). (pubmed)

11. Perera RM and Bardeesy N. Ready, Set, Go: The EGF Receptor at the Pancreatic Cancer Starting Line. Cancer Cell, 2012 Sept 11; 22: 281-2. (pubmed)

12. Perera RM and Bardeesy N. On oncogenes and tumor suppressor genes in the mammary gland. Cold Spring Harb Perspect Biol. 2012 Jun 1;4(6). (pubmed)

13. Perera RM and Bardeesy N. Cancer: When antioxidants are bad. Nature, 2011 July 6; 475: 43-44. (pubmed)

14. Nakatsu F, Perera RM, Lucast L, Zoncu R, Domin J, Gertler F, Toomre D, De Camilli P. The inositol 5-phophatase SHIP2 regulates endocytic clathrin-coated pit dynamics. J Cell Biol, 2010 Aug 9; 190(3):307-15

15. Rothenberg SM, Mohapatra G, Rivera MN, Winokur D, Greninger P, Nitta M, Sadow PM, Sooriyakumar G, Brannigan BW, Ulman MJ, Perera RM, Wang R, Tam A, Ma XJ, Erlander M, Sgroi DC, Rocco JW, Lingen MW, Cohen EE, Louis DN, Settleman J, Haber DA.  A genome-wide screen for microdeletions reveals disruption of polarity gene components in diverse human cancers.  Can Res, 2010 Mar 15; 70(6):2158-64  

16. Zoncu R*, Perera RM*, Balkin D, Pirruccello M, Toomre D, De Camilli P. A phosphoinositide switch controls the maturation and signaling properties of APPL endosomes. Cell 2009 Mar 20; 136(6):1110-21    *equal contributors (pubmed)

17. Frost A, Perera R, Roux A, Spasov K, Destaing O, Egelman EH, De Camilli P and Unger VM. Structural basis of membrane tubule formation by F-BAR domains. Cell 2008 Mar 7; 132(5):807-17. 

18. Johns TG, Perera RM, Vernes SC, Vitali AA, Cao DX, Cavenee WK, Scott AM and Furnari FB.  The efficacy of EGFR specific antibodies against glioma xenografts is influenced by receptor levels, activation status and heterodimerization.  Clin Can Res, 2007 Mar 15; 13(6):1911-1925 (cover page)

19. Perera RM, Zoncu R, Johns TG, Pypaert M, Lee FT, Mellman I, Old, LJ, Toomre DK and Scott AM. Internalization, intracellular trafficking and biodistribution of monoclonal antibody 806: A novel anti-EGFR antibody.  Neoplasia 2007 Dec 9;(12):1099-110

20. Zoncu R, Perera RM, Sebastian R, Nakatsu F, Chen H, Balla T, Ayala G, Toomre D and De Camilli P. Loss of endocytic clathrin coated pits upon acute depletion of phosphatidylinositol 4,5 bisphosphate.  PNAS  2007 Mar; 104(10): 3793-8

21. Perera RM, Zoncu R, Lucast L, De Camilli P, Toomre D.  Two isoforms of synaptojanin 1 are recruited to clathrin coated pits at different stages. PNAS 2006 Dec; 103(51):19332-7

22. Perera RM, Narita Y, Furnari FB, Gan HK, Murone C, Ahlkvist M, Luwor RB, Burgess AW, Stockert E, Jungbluth AA, Old LJ, Cavenee WK, Scott AM and Johns TG.  Treatment of human tumour xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Clin Can Res, 2005 Sept 1; 11(17):6390-9

23. Luwor RB, Zhu H-J, Walker F, Vitali AA, Perera RM, Burgess AW, Scott AM and Johns TG.  The tumor specific de2-7 epidermal growth factor receptor (EGFR) promotes cell survival and heterodimerizes with the wild type EGFR.  Oncogene, 2004 Aug 12;23(36):6095-104

24. Johns TG, Luwor RB, Murone C, Walker F, Weinstock J, Vitali AA, Perera RM, Jungbluth AA, Stockert E, Old LJ, Nice EC, Burgess AW and Scott AM.  Anti-tumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the epidermal growth factor receptor (EGFR) inhibitor AG1478.  PNAS, 2003 Dec;100(26):15871-15876